All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
20 results for "Cancer" and "Skin Cancers" and "Leukemia"
Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3-zeta; and 4-1BB Signaling Domains in Pediatric and Young Adult Patients with Relapsed and/or Refractory CD19 or CD20 B-cell Acute Lymp
Phase 1 Study of CAR-20/19-T Cells in Pediatric and Young adult Patients with R/R B Cell ALL
Protocol No
IIT-TALANO-CART-ALL
Sub Category
A Phase 1b/2 Study of the Safety, PK, PD and Preliminary Efficacy of the FLT3 Inhibitor Gilteritinib, in Combination with the Selective SYK Inhibitor Lanraplenib (KB-9876), in Patients with FLT3-mutated Relapsed or Refractory AML
To evaluate the safety of LANRA in combination with the FLT3 inhibitor gilteritinib, in patients with R/R FLT3-mutated AML.
Protocol No
KRONOS-KB-LANRA-1001
Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Pa
Phase II/III Study of ALVR105 After Allogeneic Hematopoietic Cell Transplant
Protocol No
ALLOVIR-P-105-202-PREVENTION
Sub Category
A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B-cell Malignancies or Acute Myeloid Leukemia after Failure of Prior Standard Therapies and Voruciclib in Combination with Venetoclax in Subjects with Relapsed and
This project is being done to determine the highest safely tolerated dose of voruciclib in patients that have relapsed and/or refractory B cell type cancers or acute myeloid leukemia.
Protocol No
MEI-ME-522-001
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety & Efficacy of Magrolimab vs Placebo in Combination w/ Venetoclax & Azacitidine in Newly Diagnosed, Previously Untreated Patients w/ AML Who Are Ineligible for Intensi
Magrolimab vs Placebo plus Venetoclax and Azacitidine in AML
Protocol No
GILEAD-GS-US-590-6154-AML
Sub Category
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
HLA-Mismatched Unrelated Donor HCT with Post-Transplantation Cyclophosphamide (Access)
Protocol No
NMDP-ACCESS
Sub Category
GILEAD-GS-US-546-5857-AML: A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine versus Venetoclax plus Azacitidine in Previously Untreated Patients with TP53 Mutant AML who are Inel
Magrolimab plus Azacitidine vs Venetoclax plus Azacitidine in Previously Untreated TP53 Mutant AML
Protocol No
GILEAD-GS-US-546-5857-AML
Sub Category
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta T Cells in Adults with Refractory B-Cell Malignancies, in Monotherapy and Combination with IL-2.
A Phase 1 Study of ADI-001 in B Cell Malignancies
Protocol No
ADICET-ADI-001-BCELL
Sub Category
Asciminib as Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase
Asciminib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase
Protocol No
HJKC3-0004
Sub Category
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Study Evaluating Safety and Efficacy of JCAR017 in Subject with rrCLL or SLL
Protocol No
JUNO-017004-TRANSCEND-CLL
Sub Category
A Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients with Virus-Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Cell Transplant
Trial of Viralym-M (ALVR105) for Patients With Virus-Associated Hemorrhagic Cystitis after allo-HCT
Protocol No
ALLOVIR-AVM-003-HC
Sub Category
Treatment Free Remission After Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Treatment Free Remission After Asciminib plus Imatinib in CP-CML
Protocol No
HJKC3-0003
Sub Category
Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
Protocol No
HJKC3-0002
Sub Category
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1- Antitrypsin (AAT) Combined with Corticosteroids vs. Corticosteroids Alone for the Treatment of High-Risk Acute Graft-versus-Host-Disease (GVHD) Following Hematopo
Alpha 1- Antitrypsin Combined with Corticosteroids vs. Corticosteroids Alone for Tx of aGVHD
Protocol No
CTN-1705
Sub Category
An Open-label, Phase 2a/2b Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post PV-MF), or Post Essential Thrombocythemia MF (Post ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor
KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor
Protocol No
KARTOS-KRT-232-101-MF
Sub Category
A Phase I Trial of Neihulizumab Monotherapy for Standard-Risk Acute GVHD
A Phase I Trial of Neihulizumab Monotherapy for Standard-Risk Acute GVHD
Protocol No
IIT-ABEDIN-NEIHULIZUMAB
Sub Category
A Phase II Study of the Efficacy and Pharmacogenomics of Salvage Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML)
Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia
Protocol No
IIT-ATALLAH-CLAGM-AML
Sub Category
A Phase II, Open-Label, Study of Propylene Glycol-Free Melphalan HCL (EVOMELA®) in Combination with Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
EVOMELA In Combination With Fludarabine and TBI based reduced intensity conditioning for Haplo BMT
Protocol No
IIT-HAMADANI-FLU-MEL-TBI
Sub Category
A Phase II, Single-Arm, Open-label Study of Itacitinib, for the Prevention of Cytokine Release Syndrome (CRS) Induced by Immune Effector Cell Therapy
A study of Itacitinib for the Prevention of CRS induced by Immune Effector Cell Therapy
Protocol No
INCYTE-INCB-39110-211-CRS
Sub Category
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
Study of tandem, bispecific anti-CD19 anti-CD20 CAR-T cells for Patients with Relapsed and/or Refractory B Cell Malignancies
Protocol No
IIT-SHAH-IL7-IL15-CD20-19
Sub Category